Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,858 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MET Exon 14-altered Lung Cancers and MET Inhibitor Resistance.
Guo R, Offin M, Brannon AR, Chang J, Chow A, Delasos L, Girshman J, Wilkins O, McCarthy CG, Makhnin A, Falcon C, Scott K, Tian Y, Cecchi F, Hembrough T, Alex D, Shen R, Benayed R, Li BT, Rudin CM, Kris MG, Arcila ME, Rekhtman N, Paik P, Zehir A, Drilon A. Guo R, et al. Clin Cancer Res. 2021 Feb 1;27(3):799-806. doi: 10.1158/1078-0432.CCR-20-2861. Epub 2020 Nov 10. Clin Cancer Res. 2021. PMID: 33172896 Free PMC article.
CNS Metastases in Patients With MET Exon 14-Altered Lung Cancers and Outcomes With Crizotinib.
Offin M, Luo J, Guo R, Lyo JK, Falcon C, Dienstag J, Wilkins O, Chang J, Rudin CM, Riely G, Rekhtman N, Arcila ME, Heller G, Ladanyi M, Li BT, Kris MG, Paik P, Drilon A. Offin M, et al. Among authors: guo r. JCO Precis Oncol. 2020 Jul 27;4:PO.20.00098. doi: 10.1200/PO.20.00098. eCollection 2020. JCO Precis Oncol. 2020. PMID: 32923895 Free PMC article.
Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers.
Offin M, Guo R, Wu SL, Sabari J, Land JD, Ni A, Montecalvo J, Halpenny DF, Buie LW, Pak T, Liu D, Riely GJ, Hellmann MD, Benayed R, Arcila M, Kris MG, Rudin CM, Li BT, Ladanyi M, Rekhtman N, Drilon A. Offin M, et al. Among authors: guo r. JCO Precis Oncol. 2019;3:PO.18.00386. doi: 10.1200/PO.18.00386. Epub 2019 May 16. JCO Precis Oncol. 2019. PMID: 31192313 Free PMC article. No abstract available.
Characterization of on-target adverse events caused by TRK inhibitor therapy.
Liu D, Flory J, Lin A, Offin M, Falcon CJ, Murciano-Goroff YR, Rosen E, Guo R, Basu E, Li BT, Harding JJ, Iyer G, Jhaveri K, Gounder MM, Shukla NN, Roberts SS, Glade-Bender J, Kaplanis L, Schram A, Hyman DM, Drilon A. Liu D, et al. Among authors: guo r. Ann Oncol. 2020 Sep;31(9):1207-1215. doi: 10.1016/j.annonc.2020.05.006. Epub 2020 May 15. Ann Oncol. 2020. PMID: 32422171 Free PMC article.
7,858 results